Priority Healthcare b (NASDAQ:PHCC)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Priority Healthcare b Charts. Click Here for more Priority Healthcare b Charts.](/p.php?pid=staticchart&s=N%5EPHCC&p=8&t=15)
Priority Healthcare is a Preferred Specialty Pharmacy Provider Of
Apokyntm, a New Therapy for Patients With Parkinson's Disease
LAKE MARY, Fla., April 26 /PRNewswire-FirstCall/ -- Priority Healthcare
Corporation has signed an agreement with Bertek Pharmaceuticals, a wholly
owned subsidiary of Mylan Laboratories Inc., , to be a preferred specialty
pharmacy provider of Apokyn(TM) (apomorphine hydrochloride injection). Apokyn,
approved April 20, 2004 by the FDA, is the first and only therapy in the United
States indicated as an acute intermittent treatment of hypomobility, or "off"
episodes, in patients with advanced Parkinson's disease. Apokyn will be
available for patient use in July.
"As both a chronic and progressive disease, Parkinson's disease has a profound
affect on the lives of sufferers. Priority Healthcare is pleased to provide
specialty pharmacy services for Apokyn," said Steve Cosler, President and CEO
of Priority Healthcare. "We are happy to establish a relationship with Bertek
with this new therapy and pleased to strengthen our continuing relationship
with Mylan Laboratories. Neurology has always been an important area for
Priority Healthcare and this therapy expands our relationship with neurologists
and movement disorder specialists."
"We are very excited to bring Apokyn to market, and look forward to providing
this product to the Parkinson's community. Our relationship with Priority
Healthcare, one of three specialty pharmacy providers we have contracted with,
ensures both patients and physicians will have their Apokyn prescription needs
fulfilled by a highly respected patient focused organization," stated James
Mauzey, President of Bertek Pharmaceuticals, Inc.
Priority Healthcare's specialty pharmacy services for Apokyn will include:
* Caring Paths(TM) disease treatment management process, specific to
Parkinson's disease.
* Expert treatment preparation by clinical pharmacists.
* Express shipping direct to homes, physician offices, or other
convenient locations.
* Detailed personal instruction and educational materials for
self-administration.
* Access to pharmacists and nurses 24 hours a day, 7 days a week, 365
days a year.
* Insurance counseling and assistance through reimbursement specialists
who oversee the submission and approval process.
* Coordination of all aspects of patient care with the physician's
office.
About Parkinson's disease
Afflicting the central nervous system, Parkinson's disease is characterized by
resting tremors, stiffness in limbs, slowness of movement, and postural
instability. Parkinson's is estimated to affect 1-1.5 million Americans, with
incidence increasing with age. As the disease progresses, patients become less
responsive to their medications, such as levodopa, and may develop motor
fluctuations referred to as "off" episodes. "Off" episodes are debilitating
periods of partial loss of movement or total immobility experienced by patients
with advanced Parkinson's disease. These episodes are characterized by
stiffness of the limbs, slowness, immobility and, in most cases, tremor.
Because patients with Parkinson's disease lose motor control during "off"
episodes, walking, eating, bathing, and even speaking may be more impaired
during an "off" episode.
About Apokyn
Apokyn does not prevent off episodes and does not replace other Parkinson's
disease medications, but rather it is used as an acute (rescue) therapy to
effectively treat an off episode when it occurs. Apokyn is given by injection
under the skin. Apokyn should not be used by patients who are being treated
with certain drugs to treat nausea and vomiting or irritable bowel syndrome.
These medications (including, for example, ondansetron, granisetron,
dolasetron, palonesetron, and alosetron) called 5HT3 antagonists or blockers.
In addition, Apokyn should not be used by patients who have an allergic
reaction to the drug or its ingredients (notably sodium metabisulfite). Apokyn
should be injected under the skin only, and not into a vein. Because Apokyn
can cause severe nausea and vomiting, it is taken with an oral medicine that
helps to prevent these effects. Apokyn may lower blood pressure (orthostatic
hypotension), cause fainting, and increase the risk of falling. At recommended
doses minimal increases in QTC were observed. Caution should be used when
prescribing apomorphine with drugs that prolong the QT/QTC interval. Some
patients treated with Apokyn may get sleepy during the day or fall asleep
without warning while doing everyday activities. The most common side effects
of Apokyn are yawning, dyskinesias, nausea and/or vomiting, sleepiness,
dizziness, runny nose, hallucinations, fluid retention, chest pain, increased
sweating, flushing, and an unusually pale complexion.
Additional information on Apokyn is available from Bertek Pharmaceuticals at:
http://www.bertek.com/
About Priority Healthcare Corporation
Priority Healthcare Corporation is a national specialty pharmacy and
distributor that provides biopharmaceuticals, complex therapies, and related
disease treatment programs and services. Priority Healthcare provides
comprehensive programs for patients, payors, physicians, and pharmaceutical
manufacturers for a growing number of disease states including cancer,
hepatitis C, respiratory and pulmonary conditions, infertility, rheumatoid
arthritis, hemophilia, multiple sclerosis, Parkinson's, and age-related macular
degeneration. Additional information regarding Priority Healthcare is
available at http://www.priorityhealthcare.com/
Certain statements included in this press release, which are not historical
facts, are forward-looking statements. Such forward-looking statements are
made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements represent our
expectations or beliefs and involve certain risks and uncertainties, including
those described in our public filings with the United States Securities and
Exchange Commission; also including, but not limited to, changes in interest
rates, competitive pressures, changes in customer mix, changes in third party
reimbursement rates, financial stability of major customers, changes in
government regulations or the interpretation of these regulations, changes in
supplier relationships, growth opportunities, cost savings, revenue
enhancements, synergies and other benefits anticipated from acquisition
transactions, difficulties relative to integrating acquired businesses, the
accounting and tax treatment of acquisitions, and asserted and unasserted
claims, which could cause actual results to differ from those in the
forward-looking statements. The forward-looking statements by their nature
involve substantial risks and uncertainties, certain of which are beyond our
control, and actual results may differ materially depending on a variety of
important factors. You are cautioned not to place undue reliance on these
forward-looking statements that speak only as of the date herein.
http://www.newscom.com/cgi-bin/prnh/20030417/PHCLOGODATASOURCE: Priority
Healthcare Corporation
CONTACT: Financial: Stephen Saft, Chief Financial Officer,
+1-407-804-6700, or Media: Kirsten Ayars, Public Relations Manager,
+1-407-804-5826, both of Priority Healthcare Corporation
Web site: http://www.priorityhealthcare.com/
http://www.bertek.com/